ing aneurysms, 31 ruptured aneurysms, 50, 60 and posterior circulation aneurysm. 42 Multiple flow diverters are currently available: the Pipeline embolization device (PED, Medtronic), Surpass (Stryker), FRED (flow redirection endoluminal device, MicroVention), SILK (Balt Extrusion), and p64 (Phenox). A new generation of intraluminal support devices incorporate braided designs with 18%-22% metal coverage and possible flow-modifying properties. These include: LVIS (low-profile visualized intraluminal support device, MicroVention), LVIS Jr. (MicroVention), and LVIS Blue (MicroVention). Incidentally, 2 overlapping LVIS devices have been reported to create a better flowdiverting effect than a single PED. 89 Other recent developments in flow diversion/disruption include intrasaccular devices such as WEB (Woven EndoBridge, Sequent Medical), Medina embolic device (Medtronic), and LUNA AES (aneurysm embolization system, Nfocus Neuromedical).
Treatment Effect and Durability
A large meta-analysis of studies including a total of 1654 intracranial aneurysms treated with flow diverters found an overall 76% occlusion rate. 13 Authors of other meta-analyses have reported similar overall occlusion rates. 92, 94 A meta-analysis reviewing blister aneurysms found that, of the reconstructive treatments, flow diverters were associated with higher rates of occlusion (90% vs 67%) and lower rates of retreatment than other reconstructive methods. 75 A recent meta-analysis of flow-diverter treatment for 225 posterior circulation aneurysms noted an 84% occlusion rate at 6 months with overall good outcomes in 79% of patients. However, patients with ruptured aneurysms and basilar artery aneurysms were significantly less likely to have a good outcome. 90 The Buenos Aires experience of 1000 patients treated with flow diverters (633 of whom were treated with PED) noted 1-year and 8-year occlusion rates of 80% and 100%, respectively, without recurrences. 57 
Complications and Technical Difficulties
A meta-analysis of flow-diverter treatment of intracranial aneurysms found that the procedure-related morbidity and mortality were 5% and 4%. 13 The rates of perforator infarction (more common in the posterior circulation) and intraparenchymal hemorrhage were 3% each. In an international retrospective study of risk factors for complications following PED treatment, 15% of intracranial hemorrhages were contralateral to the side of PED placement. 12 Speculation exists about the cause of intraparenchymal hemorrhage, especially contralateral to the device. Theories include embolized sheath material with hemorrhagic transformation of ischemic infarct in the setting of dualantiplatelet therapy, flow changes, and platelet dysfunction from shear over the device. Another meta-analysis examining only posterior circulation aneurysms noted a 15% mortality rate among patients treated with flow diversion, with the risk of mortality being greater in patients with giant aneurysms; ischemic and perforator infarcts were observed in 11% and 7% of patients, respectively. 90 In a recent study incorporating diffusion-weighted imaging performed 24 hours after PED placement, 62% of patients were found to have clinically silent ischemic infarcts. 6 Ipsilateral FLAIR changes of uncertain etiology and consequence have been identified in 34% of patients. 78 Higher rates of complications have been reported for the treatment of aneurysms in the posterior circulation and distal cerebral vasculature. 58 Rangel-Castilla et al. 74 found a long-term rate of side-branch occlusion of 15.8% after flow-diverter treatment; however, these occlusions appeared to be clinically silent. Terminal branch occlusions in vessels such as the anterior choroidal artery were not observed. Colby et al. 22 noted that resheathing occurred in 9% of Pipeline Flex cases, and 98% of devices were successfully placed in their series. Delayed aneurysm rupture after PED use has been reported and may result in carotid-cavernous fistula. Roy et al. reported a 11.4% rate of carotid-cavernous fistula occurrence after PED treatment, with all of the fistulas occurring within 2 weeks of PED placement. 76 In a study of 17 patients treated with flow diversion, Berge et al. 5 noted that 41% experienced an exacerbation of symptoms related to perianeurysmal edema and inflammation after treatment. MRI findings have supported this inflammation theory. 5 The RADAR study (Retrospective Analysis of Delayed Aneurysm Ruptures after Flow Diversion) 49 reported a 2.1% risk of delayed ruptured for aneurysms larger than 10 mm in diameter (mean 24 mm), with a median time from treatment to rupture of 9 days. Potential mechanisms of delayed rupture include persistent inflow jet after treatment, thrombosis/expansion of the aneurysm due to stagnation of flow, and clot-induced autolysis of the aneurysmal wall.
14, 48 John et al. 38 reported a 9.8% rate of in-stent stenosis at a median of 6 months after PED treatment. However, no significant clinical effects occurred, and there was significant improvement at further follow-up noted related to the stenosis; no stenosis required retreatment. PED migration can also occur, and was reported in 0.5% of cases in one study. 17 Persistent aneurysm growth following PED placement has been reported for a fusiform VA aneurysm. 43 The IntrePED study 41 retrospectively assessed neurological complication rates with PED. A total of 906 aneurysms were included, and the overall rate of neurological morbidity and mortality was 8.4%; the rate was highest in cases of posterior circulation aneurysms (16.4%). The lowest neurological morbidity and mortality rate in that study was for small (< 10 mm) ICA aneurysms (4.8%). The spontaneous rupture rate was 0.6%, and the rates of ischemic and hemorrhagic strokes were 4.7% and 2.4%, respectively. The rate of ischemic stroke in the posterior circulation was 7.3%. In a more recent study utilizing the same registry, Brinjikji et al. 11 found a 4.5% rate of ischemic stroke. Variables contributing to acute ischemic stroke included male sex, hypertension, fusiform aneurysm, middle cerebral artery (MCA) aneurysm, giant aneurysm, and multiple PEDs. However, on multivariable analysis the only variable associated with postoperative stroke was fusiform aneurysm. 11 The recently published ASPIRe study 39 prospectively analyzed occlusion rates and neurological events following PED placement. Two hundred seven aneurysms were treated (mean aneurysm size of 14.5 mm, median imaging follow-up of 7.8 months). This study reported neurological morbidity and mortality rates of 6.8% and 1.6%, respectively. The rate of complete occlusion on last imaging follow-up was 74.8%. The au-thors concluded that PED treatment of aneurysms in a heterogeneous population was safe, with low neurological morbidity rates and good occlusion rates.
Lastly, flow diversion does not work for all aneurysms. Persistent posttreatment filling of posterior communicating artery aneurysms associated with a fetal posterior cerebral artery have been reported in patients treated with PED. 93 Another study of PED use for 16 aneurysms with an incorporated vessel supplying a territory without collateral circulation (end territory) revealed persistent patency of all aneurysms at 24 months after treatment. The aneurysm locations were as follows: posterior communicating artery (n = 7), ophthalmic (n = 5), superior cerebellar artery (n = 1), anterior inferior cerebellar artery (n = 1), and MCA aneurysms (n = 2). 42 Paraophthalmic aneurysms with the ophthalmic artery origin from the dome appear to have lower rates of occlusion and ophthalmic artery patency, as well as more transient visual symptoms. 35 In comparison with PED treatment of previously untreated aneurysms, PED treatment of previously stented, recurrent aneurysms is associated with higher morbidity and lower occlusion rates.
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Endoluminal Flow-Diverter Devices
Please see Table 1 for a tabular comparison of devices.
Pipeline
The Pipeline embolization device (PED) is a self-expanding cylindrical device. It is composed of 48 braided strands of cobalt-chromium and platinum-tungsten wire in a 3:1 ratio. The device ranges from 2.5 to 5 mm in diameter and from 10 to 35 mm in length and opens 0.25 mm wider than the nominal diameter. The device is mounted by stretching it and covering it with a delivery sheath; the distal edge is protected beneath a capture coil. The device's metal coverage depends heavily on the method of deployment (pushing vs unsheathing) and also on vessel tortuosity if the devices are telescoped. For example, a 4.75-mm PED in a 5-mm vessel has approximately 27% ± 4% metal coverage. The same device in a 3-mm vessel has only 18% ± 3% coverage. As vessel diameter decreases further, the metal coverage increases again. On the other hand, a 4.25-mm PED in a 4.5-mm vessel has 36% metal coverage due to passive expansion to a 4.5-mm diameter, permitting some frontloading and decreased porosity. 80 The Pipeline Flex embolization device, a newer generation implant, allows the operator greater flexibility and the ability to resheath up to a certain point (Fig. 1) . 66 Before the Flex device became available, an incorrectly placed Pipeline device would need to be "corked" and pulled into the guide for removal.
Some deployment pearls for PED placement from Shapiro et al. 80 based on benchtop experiments include the following. 1) Oversizing over a fusiform lesion will lead to a transition zone with less metal coverage distally, which in the smaller artery can produce a lip/endoleak. No degree of loading will resolve this. Two devices are necessary. 2) Oversizing with a small landing zone can lead to the device edges assuming a conical appearance. If the device is deployed under tension, foreshortening with prolapse into the aneurysm can occur.
The Pipeline Flex is typically deployed through a 0.027-inch ID (inner diameter) microcatheter such as Marksman (Covidien/Medtronic), Headway 27 (Microvention), or Phenom (Medtronic). Some surgeons use an intermediate support catheter for stability. In tortuous anatomy, a larger guide catheter is also used. PED deployment can be complicated by torsion and failed device opening, as well as stretching of the microcatheter in tortuous anatomy. The best strategy for managing torsion is early recognition and prevention. If it occurs, "swaging" the PED by moving the catheter back and forth may help with different amounts of loading and stretching. Incomplete opening or failed opening maneuvers include, as a last resort, intra-DIC (distal intracranial catheter) deployment or utilizing 54 Balloon angioplasty within the partially expanded PED may be required.
The PITA study (The Pipeline Embolization Device for the Intracranial Treatment of Aneurysms), 63 the first multicenter prospective trial of PED treatment, studied 31 aneurysms, predominantly involving the proximal and distal cavernous ICA (mean aneurysm size 11.5 mm, mean neck diameter 5.8 mm). Fifteen lesions were treated with PED alone, while another 15 were treated with coils and PED. The occlusion rate was 93% at 6 months with 2 major strokes. The PUFS study (Pipeline for Uncoilable or Failed Aneurysms) 3 prospectively assessed 107 patients with a mean aneurysm size of 18 mm; 20% of the aneurysms were giant. The aneurysm occlusion rate was 73% at 180 days with a major stroke rate of 5.6%. Recently, the PUFS 3-year follow-up results were released by Becske et al. 4 At 3 years after treatment, 74 patients had undergone follow-up angiography, which showed complete angiographic occlusion in 93.4%. Of the 103 surviving patients, 85 underwent functional outcome assessment, and 80 of these patients had modified Rankin Scale scores of 0-1. No recanalization of previously occluded PED-treated aneurysms was noted over 3 years. Five aneurysms required retreatment. This study reported a 2.6% delayed aneurysm or device-related serious adverse event rate, with no lasting neurological sequelae. The authors concluded that PED was safe and effective for complex large and giant aneurysms of the ICA. Furthermore, the device led to progressive vascular remodeling, with high rates of complete occlusion on longer-term follow-up.
Numerous other groups have reported their experience with PED use. Recently, the long-term results of the Buenos Aires experience with flow diversion were published. In their series of 1000 patients, 633 patients were treated with PED. A history of subarachnoid hemorrhage was present in 18.5% all study participants. Eight-year followup demonstrated 100% aneurysm occlusion. A 98% technical success rate was reported, along with a 5.9% periprocedural morbidity and mortality rate. 57 The Barcelona 83 and Canadian 64 experiences with PED for aneurysms also demonstrated positive results.
The device has also been used in off-label applications for distal lesions, with one study reporting an occlusion rate of 84% following PED treatment of MCA aneurysms. 91 Distal anterior cerebral artery aneurysms are also amenable to treatment with PED. 55 PED uses for small anterior circulation aneurysms have also shown good occlusion rates, with risk profiles similar to those for stentassisted coiling.
18
Surpass
The Surpass flow diverter is a self-expandable braided tubular structure composed of cobalt-chromium (30% metal coverage) (Fig. 2) . The longest device is 50 mm, and the widest 5.3 mm. While the 2-mm device has 48 braided wires, the 3-to 4-mm devices have 72 braided wires, and the 5-mm device has 96 wires, providing a more uniform pore density over different sizes. In addition, the filament sizes change from 25 to 36 mm, depending on the device diameter. The braid angle was especially designed to prevent changes in mesh density around curves and also to minimize foreshortening (Fig. 2) . 87 The device is resheathable up to 11 mm between catheter tip and pusher. The Surpass device is loaded within a 3.7-Fr distal catheter with a pusher catheter and accepts a 0.014-inch microguide wire. Experienced neurointerventionalists and neurosurgeons have found this Surpass device technically easier to deploy than other flow diverters.
In a multicenter trial by Wakhloo et al., 87 165 patients with anterior and posterior circulation aneurysms were treated with Surpass with a 98% technical success rate and an average of 1.05 devices per aneurysm. At follow-up, 75% of aneurysms showed complete occlusion. The rates of permanent neurological morbidity and mortality were 6% and 2.7%, respectively. The incidence rate for ischemic stroke within 30 days was 3.7%, and the incidence rate for intraparenchymal hematoma at less than 7 days was 2.5%. Dilatation was required after device placement in 19% of cases due to inadequate intimal apposition. Guidewire perforation occurred in 3.1% of cases. In another cohort of 20 patients with large ICA aneurysms (> 10 mm) and tortuous anatomy of the arch or cervical/cavernous ICA, Surpass device placement was successful, demonstrating navigability. 23 The Surpass device is being studied in an ongoing clinical trial (the Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms [SCENT], clinicaltrials.gov registration no. NCT01716117).
FRED
The FRED (flow redirection endoluminal device) differs significantly in design from the 2 previously described flow diverters, being a self-expanding dual-layer braided construct, or a stent within a stent. The inner layer has low porosity (48 braided nitinol wires), while the outer layer has high porosity (16 nitinol wires). An interwoven tantalum layer provides radiopacity and connects the inner and outer layers. The inner and outer layers are only present over the central 80% of the device. Sizes range from 3.5 to 5.5 mm and lengths from 7 to 56 mm. Resheathing is possible until 80% of the device is unsheathed (Fig. 3 ). An 0.027-inch-ID microcatheter is used for deployment. 61 Möhlenbruch et al. 61 examined 29 patients with 34 aneurysms that had been treated with FRED placement. The technical success rate for device placement was 100%. At 6-month follow-up, 22 of 30 aneurysms were occluded. There was 1 disabling stroke and 2 minor strokes. Another study of 37 patients noted a 3% procedural complication rate. At follow-up, fish-mouthing or foreshortening of the device was found to have occurred in 5 patients. The rate of aneurysm occlusion was 32% at 0-1 month and 100% (8 of 8 cases) at 7-12 months. 46 A single-center study from Italy noted complete occlusion in 20 of 24 aneurysms treated with the FRED system and intraprocedural and postprocedural complication rates of 4% and 12%, respectively. 
SILK
The SILK flow-diverting device is a flexible self-expanding tubular structure composed of braided mesh with flared ends. The device is composed of 48 nickel-titanium (nitinol) and platinum microfilaments roughly 35 mm in size and was designed to provide 35%-55% metal coverage with a pore size of 110-250 mm at the nominal diameter. 47 A systematic review 62 of SILK flow-diverter cases found 285 patients reported on in the literature; 86% of their aneurysms were anterior circulation lesions, and 44% and 17% of aneurysms were classified as large or giant, respectively. Ischemic complications occurred in 10% of patients, and the aneurysm rupture rate was 3.5%, with a cumulative mortality of 4.9%. The 12-month aneurysm occlusion rate was 81%. The authors concluded that the SILK device achieves high rates of occlusion but may carry higher rates of ischemic injury and mortality. 62 A recently published Canadian study 79 of 92 SILK-treated cases noted 83% complete or near-complete occlusion at last followup. Aneurysm size ranged from 2 to 60 mm. The perioperative morbidity and mortality rates were 8.7% and 2.2%, respectively. The authors concluded that the SILK flow diverter is an important tool for complex aneurysms, but complication rates remain a problem. They did go on to say, however, that complication rates should be assessed in the context of available alternatives. Another recent study of complex intracranial aneurysms concluded that SILK is a good treatment option for anterior circulation lesions, but additional stents may be required due to the low opening force of SILK. The authors also stated that treatment of large posterior circulation aneurysms with SILK flow diverters carries a high rate of severe complications. 81 An earlier study of 12 patients with basilar aneurysms undergoing SILK placement noted 1 case of acute basilar occlusion and 3 cases of delayed neurological events at a mean of 16 weeks. The authors concluded that SILK device placement in the basilar artery is feasible and well tolerated in most, but late ischemic events do occur, and the device should be reserved for otherwise untreatable lesions. 47 Two studies assessed both PED and SILK and found comparable morbidity and clinical outcomes. 10, 59 Ongoing studies include the MARCO POLO postmarket clinical investigation (Multicenter Randomized Trial on Selective Endovascular Aneurysm Occlusion with Coils versus Parent Vessel Reconstruction with the SILK Flow Diverter, www.clinicaltrials.gov registration no. NCT01084681).
p64
The p64 flow-modulation device allows full deployment with recoverability. The device is composed of 64 braided nitinol wires. It is delivered via a 0.027-inch-ID microcatheter, and once unsheathed, is mechanically detached. The diameter ranges from 2.5 to 5 mm and the length from 12 to 36 mm. Detachment occurs in 4 steps once the device is positioned: Step 1, peel-away sheath is removed; Step 2, white torque is loosened; Step 3, another torque is placed proximal to the detachment tubing and tightened to the delivery wire; and Step 4, detachment is completed by pulling the proximal end of the polymer tube toward the torque. The p64 device is deployed via wire pushing and catheter unsheathing. 7 The detachment mechanism was validated in a small series of 6 aneurysms, demonstrating 100% success in immediately reducing aneurysm inflow with all devices. 7 There was no morbidity or mortality. In a larger series of 121 patients treated with p64, complete occlusion was seen in 79% of followed lesions at 9 months posttreatment. Late follow-up showed complete occlusion in 30 of 35 lesions at a median follow-up period of 496 days. The rates of transient and permanent morbidity were 5% and 1.7%, respectively, and the mortality rate was 0.8%. 30 A recent study of 40 patients treated with p64 reported complete occlusion in 88%, permanent morbidity in 2.5% due to in-stent thrombosis, and technical complications in 16%. 8 
Intrasaccular Flow Diversion/Disruption
Intrasaccular devices, as a group, provide high metal coverage at the aneurysm neck, but unlike the endoluminal flow-diversion devices, these devices are placed within the aneurysm itself. A theoretical advantage is possibly a decreased need (or no need) for adjunct antiplatelet therapy. See Table 2 for a tabular comparison of these devices.
Woven EndoBridge
The Woven EndoBridge (WEB) device (Sequent Medical) is an endosaccular/intrasaccular flow diverter/disrupter composed of braided nitinol wires with proximal and distal platinum markers (Fig. 4) . The wire mesh spanning the aneurysm inflow provides 35%-45% metal coverage. The device has an inner and outer wire mesh, forming 2 compartments. The stent-like structure of the device provides adherence to the aneurysm wall (Fig. 4) . The device is deployed in a manner similar to available stents or coils and has an electrothermal detachment system.
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The WEB device comes in 2 configurations: standard (SL, "single layer") and spherical (SLS, "single layer sphere"). The WEB SL is available in a diameter range of 4-11 mm and a height range of 3-9 mm.
The initial clinical experience with WEB was reported in 2011 after implantation into unruptured basilar artery apex and MCA trifurcation aneurysms. Short-term angiographic follow-up at 8 weeks posttreatment revealed complete aneurysm occlusion. 45 Results from a multicenter trial 69 including 20 patients showed 80% adequate occlusion of wide-necked aneurysms at 2-8 months. One patient experienced transient worsening due to a thromboembolic event, and 23.8% of patients underwent additional stent or coil placement. This study also had 1 inadvertent WEB deployment. Lubicz et al. 56 examined WEB for treatment of wide-necked bifurcation aneurysms and noted successful deployment in 18 of 19 patients and improved or stable follow-up angiography in all but 4 cases. Pierot et al. 68 treated 34 MCA aneurysms with WEB; 85% of the aneurysms were unruptured, and neck sizes were 4 mm or greater in 88% of cases. The WEB device was used exclusively for 88% of aneurysms. One intraoperative rupture was noted in this study. At 2-12 months' follow-up, 83% of aneurysms had adequate occlusion (total occlusion or neck remnant). There was a 15.6% thromboembolism rate, prompting commentary regarding the need for antiplatelet agents, given the amount of metal coverage at the aneu- 67 study was published, including 51 patients at multiple centers. Treatment with WEB was achieved in 94% of patients; the rate of thromboembolic events was 17.6%, with a permanent deficit in 1 patient. One patient died, but this death was related to the patient's ruptured aneurysm status on entry into the study. Success (stable neck remnant or complete occlusion and no worsening in angiographic appearance) at 6 months was achieved in 85% of patients. The WEB-CAST 2 70 study evaluating the second-generation device (SL and SLS) reported 79% overall adequate occlusion on follow-up, with 1-month morbidity and mortality rates of 1.8% and 0%, respectively. Van Rooij et al. 86 used WEB in 32 ruptured aneurysms with an average size of 4.9 mm and wide necks in 75% of cases. No adjunctive stents or other devices were used. Three thromboembolic events occurred; only 1 patient developed an infarction. The procedural complication rate was 3%. Seven patients died due to sequelae of the subarachnoid hemorrhage. Follow-up angiography was performed at 3 months in 18 cases and revealed that 16 (89%) of 18 aneurysms were occluded. No rehemorrhages occurred during follow-up, and the authors concluded that WEB was safe and effective for small, ruptured aneurysms without adjunctive devices or anticoagulation. Clajus et al. 20 reported on 108 consecutive WEB placements; 41% were in ruptured aneurysms. Rerupture after WEB implantation was detected in 2 aneurysms, both in patients who had presented with subarachnoid hemorrhage. The authors reported a 10% thromboembolic rate and a 75% adequate occlusion rate; 15% of the aneurysms required retreatment.
LUNA AES
The LUNA AES (aneurysm embolization system) is a self-expanding double-layer nitinol mesh with platinum markers. The device is delivered via a standard 0.027-inch microcatheter and takes an ovoid shape within the aneurysm. 51 Piotin et al. 73 reported in 2012 a small prospective clinical study involving 15 patients with 14 unruptured and 1 ruptured saccular aneurysms. The aneurysm size was between 5-6.7 mm, and the aneurysms were distributed as follows: paraophthalmic (5 cases), anterior choroidal (3), posterior communicating (3), middle cerebral (2), internal carotid (1), and anterior cerebral artery (1). There was 1 failed procedure, 1 failed detachment, 4 balloon-assisted deployments, 1 rupture, and 1 thromboembolic event. In 2014, Piotin et al. 71 reported LUNA AES results for 63 patients treated at 9 European centers. At 12 months (n = 31), complete occlusion was observed in 38.7% and nearcomplete occlusion in 32.2%. Periprocedural safety events were noted in 6.25% of cases and included occlusion of the parent artery with LUNA and cavernous rupture during LUNA delivery. The overall mortality rate was 0%, and at 6 months' posttreatment there were no safety events. In 2015, the 12-month follow-up results of the European LUNA study 72 were reported. Most aneurysms were unruptured bifurcation or terminal aneurysms less than 10 mm in maximum diameter. A total of 63 patients were included; 35 adverse events occurred in 21 patients, with 24 events being classified as serious. Adjunctive devices were used in 6 cases. Angiographic follow-up at 12 months (n = 44) revealed a 77% rate of complete or near-complete occlusion. The authors concluded that the 12-month results demonstrated a good safety profile and good results on angiographic follow-up.
Medina
The Medina embolic device (Medtronic) is a 3D coil made from shape-set core wire with shape-set alloy outer filaments forming petals. The coil is deployed linearly through a microcatheter but assumes a spherical shape within the aneurysm, providing neck coverage with the petals and stable intrasaccular structure with its 3D shape. It is available in framing and filling styles. 85 Turk et al. 85 reported an early human experience in 5 patients (9 aneurysms) in 2016. An early clinical experience involving 15 patients with at least 5-mm aneurysm fundi was reported in 2017. 1 The authors reported successful deployment in all but 1 case and the need for adjunctive devices in 10 cases. There were 3 complications, but none could be attributed to the device. Follow-up angiography in 11 patients showed complete aneurysm exclusion in 4 patients, stable neck remnants in 6 patients, and an enlarging neck remnant in 1 patient. The authors raised several good points regarding the limitations of Medina as an intrasaccular flow diverter. First, many aneurysms are not spherical and/or have blebs. It is sometimes necessary to use adjunctive devices to coil blebs (to stabilize the device and prevent bleb rupture from a poorly placed device that could direct flow toward the bleb) or use interval endoluminal flow diversion for neck remnants. Second, if they are considering using both endoluminal and intrasaccular flow diversion, the authors do not use many Medina coils, as this can lead to increased thrombogenicity.
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Antiplatelet Therapy and Flow Diversion
We typically use dual-antiplatelet therapy with aspirin 325 mg and clopidogrel 75 mg for 5 days before the procedure and find that this results in therapeutic levels on platelet function tests for endoluminal flow-diverter placement. If therapeutic levels are not achieved with this treatment, we will administer a loading dose and recheck levels prior to proceeding. We rarely use glycoprotein IIb/IIIa (GpIIb/ IIIa) inhibitors up front; typically they are reserved for patients with acute in-stent thrombosis. We continue aspirin treatment indefinitely, and clopidogrel treatment is typically stopped around 6 months unless the patient was already taking this medication for another reason. Both the PUFS 3 and PITA 63 studies used dual-antiplatelet therapy in their PED treatment protocol. Recently, however, the need for dual-antiplatelet therapy has been called into question. Colby et al. 21 reported an 8% rate of transient neurological deficits, with no permanent deficits, after treatment with GpIIb/IIIa inhibitors for patients undergoing PED placement who were clopidogrel hyporesponders (P2Y12 reaction units > 200). The authors suggested a diminutive role for clopidogrel in preventing thromboembolic events in PED cases. The first reported PED with Shield Technology was recently placed for a ruptured dissecting aneurysm of the VA with only aspirin and a single loading dose of a GpIIb/IIIa inhibitor. 19 Shield Technology (Medtronic) is under study for the PED to reduce thrombogenicity. Shield Technology is a phosphorylcholine coating that through molecular mimicry was designed to decrease thrombogenicity and hopefully decrease or alleviate the need for antiplatelet agents.
33 Other options for ruptured aneurysms include preprocedural aspirin followed by clopidogrel loading at the conclusion of the procedure. Use of this regimen has also been reported for stent-assisted coiling in acute treatment of ruptured aneurysms. 82 In a recent survey of academic cerebrovascular neurosurgeons, 100% of survey respondents reported using dual-antiplatelet therapy with aspirin and clopidogrel as their first-line choice; 42.3% of responders indicated that they used aspirin and ticagrelor for clopidogrel hypo-or nonresponders, and the same percentage indicated that they used aspirin and prasugrel in such cases.
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Intrasaccular flow diversion was designed with the intended advantage of not requiring dual-antiplatelet therapy, given that the parent vessel is exposed to less metal than with endoluminal devices. However, Pierot et al. 68 noted a 15.6% thromboembolism rate for intrasaccular flow disruption with the WEB device in MCA aneurysms. All 5 thromboembolic events occurred in patients who were either not treated with any antiplatelet medication or treated with only 1 antiplatelet medication; 3 of the events were noted intraoperatively and treated with thrombolytics. This finding led to expert commentary as noted above, suggesting consideration of dual-antiplatelet therapy given the amount of metal at the aneurysm neck. For comparison's sake, commonly quoted ranges for stroke rates during aneurysm coiling are 2%-9%, and higher for asymptomatic events. 65 This has led some groups to perform platelet function tests for elective aneurysm coiling and stratify patients to different regimens depending on the results.
2
Future Directions and Limitations
While long-term data are becoming available for PEDtreated aneurysms, there is still a lack of long-term data on aneurysms treated with other types of flow diversion, both endoluminal and intrasaccular. More randomized studies with long-term follow-up will be needed to determine if all types of flow diversion ultimately lead to a lasting cure. New flow diverters continue to be designed and developed, with FloWise, another flow diverter, being tested in animal models recently. 44 Ultimately, comparative studies of each flow diverter versus each of the others will be needed to determine if niches are better suited to certain devices or if one device is safer than another. In addition, the combination of intrasaccular and endoluminal flow diversion will need to be better explored. Lastly, the application of flow diverters to ruptured aneurysms will only become commonplace if these devices achieve a low incidence of thrombogenicity. The PREMIER study (Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device, clinicaltrials.gov registration no. NCT02186561) is currently under way and was designed to expand the current indication of PED use from ICA aneurysms proximal to the posterior communicating artery to include posterior circulation aneurysms and those aneurysms distal to the posterior communicating segment of the ICA.
Conclusions
Flow diversion, both endoluminal and intrasaccular, represents a cutting-edge treatment for intracranial aneurysms that is quickly becoming the standard of care for many types of aneurysms and vascular disease. While long-term data on the PED are becoming more available and promising, more studies are needed to validate the long-term treatment value of other existing devices and new devices to come. 
